Donor HLA-E Status Associates with Disease-Free Survival and Transplant-Related Mortality after Non In Vivo T Cell-Depleted HSCT for Acute Leukemia

Chrysanthi Tsamadou, Daniel Fürst, Tao Wang, Naya He, Stephanie J. Lee, Stephen R. Spellman, Katharina Fleischhauer, Katharine C. Hsu, Sophie Paczesny, Michael R. Verneris, Hubert Schrezenmeier, Joannis Mytilineos

Research output: Contribution to journalArticle

Abstract

Previous studies have suggested that HLA-E may have a significant role in the outcome of matched unrelated hematopoietic stem cell transplantation (HSCT), especially for patients with acute leukemia. We used Center for International Blood and Marrow Transplant Research data and samples of 1840 adult patients with acute leukemia and their 10/10 HLA-matched unrelated donors to investigate the impact of HLA-E matching status as well as of donor/recipient (D/R) HLA-E genotype on post-HSCT outcome. Both patients and donors were HLA-E genotyped by next-generation sequencing. All patients received their first transplant in complete remission between 2000 and 2015. Median follow-up time was 90 months. Overall survival, disease-free survival (DFS), transplant-related mortality (TRM), and relapse incidence were primary endpoints with statistical significance set at .01. D/R HLA-E genotype analysis revealed a significant association of donor HLA-E*01:03/01:03 genotype with DFS (hazard ratio [HR] = 1.35, P = .0006) and TRM (HR = 1.41, P = .0058) in patients who received T cell replete (ie, without in vivo T cell depletion) transplants (n = 1297). As for D/R HLA-E matching, we did not identify any significant effect on any of the clinical outcome endpoints. In conclusion, this is the largest study to date reporting an improvement of DFS and TRM after matched unrelated HSCT by avoidance of HLA-E*01:03 homozygous donors in patients transplanted with T cell replete grafts for acute leukemia.

Original languageEnglish (US)
JournalBiology of Blood and Marrow Transplantation
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Hematopoietic Stem Cell Transplantation
Disease-Free Survival
Leukemia
Tissue Donors
T-Lymphocytes
Transplants
Mortality
Genotype
Unrelated Donors
Bone Marrow
Recurrence
Survival
Incidence
Research

Keywords

  • Acute Leukemia
  • DFS
  • Donor HLA-E
  • In vivo T cell depletion
  • TRM
  • Unrelated HSCT

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Donor HLA-E Status Associates with Disease-Free Survival and Transplant-Related Mortality after Non In Vivo T Cell-Depleted HSCT for Acute Leukemia. / Tsamadou, Chrysanthi; Fürst, Daniel; Wang, Tao; He, Naya; Lee, Stephanie J.; Spellman, Stephen R.; Fleischhauer, Katharina; Hsu, Katharine C.; Paczesny, Sophie; Verneris, Michael R.; Schrezenmeier, Hubert; Mytilineos, Joannis.

In: Biology of Blood and Marrow Transplantation, 01.01.2019.

Research output: Contribution to journalArticle

Tsamadou, Chrysanthi ; Fürst, Daniel ; Wang, Tao ; He, Naya ; Lee, Stephanie J. ; Spellman, Stephen R. ; Fleischhauer, Katharina ; Hsu, Katharine C. ; Paczesny, Sophie ; Verneris, Michael R. ; Schrezenmeier, Hubert ; Mytilineos, Joannis. / Donor HLA-E Status Associates with Disease-Free Survival and Transplant-Related Mortality after Non In Vivo T Cell-Depleted HSCT for Acute Leukemia. In: Biology of Blood and Marrow Transplantation. 2019.
@article{3c48b47cc98949d686a0dce494c2722b,
title = "Donor HLA-E Status Associates with Disease-Free Survival and Transplant-Related Mortality after Non In Vivo T Cell-Depleted HSCT for Acute Leukemia",
abstract = "Previous studies have suggested that HLA-E may have a significant role in the outcome of matched unrelated hematopoietic stem cell transplantation (HSCT), especially for patients with acute leukemia. We used Center for International Blood and Marrow Transplant Research data and samples of 1840 adult patients with acute leukemia and their 10/10 HLA-matched unrelated donors to investigate the impact of HLA-E matching status as well as of donor/recipient (D/R) HLA-E genotype on post-HSCT outcome. Both patients and donors were HLA-E genotyped by next-generation sequencing. All patients received their first transplant in complete remission between 2000 and 2015. Median follow-up time was 90 months. Overall survival, disease-free survival (DFS), transplant-related mortality (TRM), and relapse incidence were primary endpoints with statistical significance set at .01. D/R HLA-E genotype analysis revealed a significant association of donor HLA-E*01:03/01:03 genotype with DFS (hazard ratio [HR] = 1.35, P = .0006) and TRM (HR = 1.41, P = .0058) in patients who received T cell replete (ie, without in vivo T cell depletion) transplants (n = 1297). As for D/R HLA-E matching, we did not identify any significant effect on any of the clinical outcome endpoints. In conclusion, this is the largest study to date reporting an improvement of DFS and TRM after matched unrelated HSCT by avoidance of HLA-E*01:03 homozygous donors in patients transplanted with T cell replete grafts for acute leukemia.",
keywords = "Acute Leukemia, DFS, Donor HLA-E, In vivo T cell depletion, TRM, Unrelated HSCT",
author = "Chrysanthi Tsamadou and Daniel F{\"u}rst and Tao Wang and Naya He and Lee, {Stephanie J.} and Spellman, {Stephen R.} and Katharina Fleischhauer and Hsu, {Katharine C.} and Sophie Paczesny and Verneris, {Michael R.} and Hubert Schrezenmeier and Joannis Mytilineos",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.bbmt.2019.08.007",
language = "English (US)",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Donor HLA-E Status Associates with Disease-Free Survival and Transplant-Related Mortality after Non In Vivo T Cell-Depleted HSCT for Acute Leukemia

AU - Tsamadou, Chrysanthi

AU - Fürst, Daniel

AU - Wang, Tao

AU - He, Naya

AU - Lee, Stephanie J.

AU - Spellman, Stephen R.

AU - Fleischhauer, Katharina

AU - Hsu, Katharine C.

AU - Paczesny, Sophie

AU - Verneris, Michael R.

AU - Schrezenmeier, Hubert

AU - Mytilineos, Joannis

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Previous studies have suggested that HLA-E may have a significant role in the outcome of matched unrelated hematopoietic stem cell transplantation (HSCT), especially for patients with acute leukemia. We used Center for International Blood and Marrow Transplant Research data and samples of 1840 adult patients with acute leukemia and their 10/10 HLA-matched unrelated donors to investigate the impact of HLA-E matching status as well as of donor/recipient (D/R) HLA-E genotype on post-HSCT outcome. Both patients and donors were HLA-E genotyped by next-generation sequencing. All patients received their first transplant in complete remission between 2000 and 2015. Median follow-up time was 90 months. Overall survival, disease-free survival (DFS), transplant-related mortality (TRM), and relapse incidence were primary endpoints with statistical significance set at .01. D/R HLA-E genotype analysis revealed a significant association of donor HLA-E*01:03/01:03 genotype with DFS (hazard ratio [HR] = 1.35, P = .0006) and TRM (HR = 1.41, P = .0058) in patients who received T cell replete (ie, without in vivo T cell depletion) transplants (n = 1297). As for D/R HLA-E matching, we did not identify any significant effect on any of the clinical outcome endpoints. In conclusion, this is the largest study to date reporting an improvement of DFS and TRM after matched unrelated HSCT by avoidance of HLA-E*01:03 homozygous donors in patients transplanted with T cell replete grafts for acute leukemia.

AB - Previous studies have suggested that HLA-E may have a significant role in the outcome of matched unrelated hematopoietic stem cell transplantation (HSCT), especially for patients with acute leukemia. We used Center for International Blood and Marrow Transplant Research data and samples of 1840 adult patients with acute leukemia and their 10/10 HLA-matched unrelated donors to investigate the impact of HLA-E matching status as well as of donor/recipient (D/R) HLA-E genotype on post-HSCT outcome. Both patients and donors were HLA-E genotyped by next-generation sequencing. All patients received their first transplant in complete remission between 2000 and 2015. Median follow-up time was 90 months. Overall survival, disease-free survival (DFS), transplant-related mortality (TRM), and relapse incidence were primary endpoints with statistical significance set at .01. D/R HLA-E genotype analysis revealed a significant association of donor HLA-E*01:03/01:03 genotype with DFS (hazard ratio [HR] = 1.35, P = .0006) and TRM (HR = 1.41, P = .0058) in patients who received T cell replete (ie, without in vivo T cell depletion) transplants (n = 1297). As for D/R HLA-E matching, we did not identify any significant effect on any of the clinical outcome endpoints. In conclusion, this is the largest study to date reporting an improvement of DFS and TRM after matched unrelated HSCT by avoidance of HLA-E*01:03 homozygous donors in patients transplanted with T cell replete grafts for acute leukemia.

KW - Acute Leukemia

KW - DFS

KW - Donor HLA-E

KW - In vivo T cell depletion

KW - TRM

KW - Unrelated HSCT

UR - http://www.scopus.com/inward/record.url?scp=85072703136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072703136&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2019.08.007

DO - 10.1016/j.bbmt.2019.08.007

M3 - Article

C2 - 31425756

AN - SCOPUS:85072703136

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

ER -